Table 1.
Patients’ results
| Characteristics | Patients without chromosome 17 abnormalities | Patients with chromosome 17 abnormalities | two‐sided P |
|---|---|---|---|
| Number of patients, N (%) | 516 (94.2) | 32 (5.8) | ΝΑ |
| Sex (male: female) | 2.49 | 1.67 | 0.317 |
| Age (at diagnosis), Median (range) | 73.6 (43.9‐89.0) | 71.0 (51.7‐86.6) | 0.779 |
| WHO 2016 (diagnosis), N (%) | 0.598 | ||
| MDS‐SLD | 17 (3.3) | 0 (0) | |
| MDS‐MLD | 149 (28.9) | 5 (15.6) | |
| MDS‐RS | 19 (3.7) | 1 (3.1) | |
| MDS with isolated del(5q) | 4 (0.8) | 0 (0) | |
| MDS‐EB‐1 | 139 (26.9) | 10 (31.3) | |
| MDS‐EB‐2 | 188 (36.4) | 16 (50.0) | |
| MDS with excess blasts (MDS‐EB) | 327 (63.4) | 26 (81.3) | 0.055 |
| Hb (g/dL), Median (range) | 9.4 (3.5‐14.7) | 8.9 (5.0‐11.2) | 0.117 |
| MCV (fl), Median (range) | 95.0 (54.1‐122.9) | 89.3 (56.0‐117.0) | 0.004 |
| Neutrophil count (×109/L), Median (range) | 1.32 (0.00‐3.40) | 1.1 (0.2‐8.5) | 0.411 |
| Platelets (×109/L), Median (range) | 99.5 (1‐813) | 100 (28‐800) | 0.418 |
| Peripheral blood blast percentage, N (%) | 0 (0‐19) | 0 (0‐10) | 0.440 |
| Cytopenias, N (%) | 0.577 | ||
| 0 | 30 (5.8) | 3 (9.4) | |
| 1 | 157 (30.4) | 6 (18.8) | |
| 2 | 209 (40.5) | 13 (40.6) | |
| 3 | 120 (23.3) | 10 (31.3) | |
| Bone marrow blast percentage, N (%) | 7 (0‐20) | 11 (1‐19) | 0.019 |
| IPSS‐R group | 0.00001 | ||
| Very low | 20 (3.9) | 0 (0) | |
| Low | 103 (20.0) | 0 (0) | |
| Intermediate | 109 (21.1) | 4 (12.5) | |
| High | 174 (33.7) | 7 (21.9) | |
| Very high | 110 (21.3) | 22 (65.6) | |
| Transfusion needs, N (%) | 318 (61.6) | 24 (75.0) | 0.319 |
| Ferritin (ng/mL), Median (range) | 357 (3‐20750) | 360 (117‐1271) | 0.709 |
| Age at 5‐azacytidine initiation (y), Median (range) | 74.0 (44.1‐89.4) | 73 (57‐85) | 0.499 |
| AML transformation, N (%)a | 200 (38.8) | 14 (43.7) | 0.848 |
| Response (IWG criteria), N (%) | 0.398 | ||
| F | 115 (22.3) | 8 (25.0) | |
| SD | 146 (28.3) | 4 (12.5) | |
| PR | 69 (13.4) | 5 (15.6) | |
| CR | 75 (14.5) | 7 (21.9) | |
| HI | 86 (16.6) | 6 (18.8) | |
| Lost to follow‐up | 25 (4.8) | 2 (6.3) | |
| Survival status (alive at data cut‐off), N (%) | 298 (58.7) | 21 (65.6) | 0.456 |
AML, acute myeloid leukemia; CR, complete remission; EB, excess blasts; F, failure; HI, hematologic improvement.; IPSS‐R, Revised International Prognostic Scoring System; MDS, myelodysplastic syndrome; MLD, multilineage dysplasia; PR, partial remission; RS, ring sideroblast; SD, stable disease; SLD, single lineage dysplasia; WHO, World Health Organization.
a
47 patients lost to follow‐up, percentage applies on the remaining patients.